Results 271 to 279 of about 160,542 (279)

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Annals of Oncology, 2016
E Felip, Federico Cappuzzo, E B Garon
exaly  

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Annals of Oncology
R Dent, H Mcarthur
exaly  

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Lancet, The, 2019
Neus Baste, Åse Bratland, Ananya Roy   +2 more
exaly  

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of Oncology, 2017
E B Garon, J W Goldman, L Gandhi
exaly  

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Lancet, The
Thuy T Tran, Montaser Shaheen, Jennifer Segar   +2 more
exaly  

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

Annals of Oncology
C I Rojas, M Schenker, D M Kowalski
exaly  

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Annals of Oncology
M S Carlino, C Mcneil, A Ribas
exaly  

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Lancet, The
Alejandro Acevedo, Noelle Cloven, Roberta Lazzari   +2 more
exaly  

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study

Annals of Oncology
D T Le, Y Zuo, D Fogelman
exaly